An international study has identified 11 new gene alterations connected to more aggressive prostate cancer using a simple blood test. The discovery could improve treatments for prostate cancer by ...
A group of scientists from the University of Surrey have shared findings from a seven-year research study, revealing that a new approach could be on the horizon for treating one of the most prevalent ...
This year, due to the COVID-19 pandemic and social distancing requirements, the PMEA Awards event will be streamed live at pmlive.com/pmea2020. After receiving a high ...
A wide range of top-performing healthcare comms agencies, charities and healthcare communicators claimed the honours at last night’s annual Communiqué Awards. The awards, run every year by PMLive’s ...
BioNTech has announced it will acquire UK AI start-up InstaDeep in a deal worth up to £562m, following the company’s initial equity investment as part of InstaDeep’s Series B financing round in ...
Pfizer and Clear Creek Bio have announced a collaboration aiming to advance the discovery and development of novel papain-like protease (PLpro) inhibitors and potentially introduce a new class of oral ...
Merck & Co is closing on a new indication for its checkpoint inhibitor Keytruda in early bladder cancer in the US, following a positive vote by an FDA expert panel. The Oncologic Drugs Advisory ...
Merck KGaA and Pfizer have staked a claim to the first-line renal cell carcinoma market, with data on a new combination that analyst say could challenge to become a new standard for the disease. The ...
A new COVID-19 subvariant, XBB.1.5, is causing concern in the US, where it has been spreading rapidly since December. Data from the US Centers for Disease Control and Prevention (CDC) has estimated ...
The European Commission (EC) has approved Roche’s highly anticipated haemophilia treatment Hemlibra (emicizumab). The rare bleeding disorder treatment, which is cleared in the EU for routine ...
AstraZeneca and Merck & Co/MSD have reported positive phase 3 data for Lynparza in advanced castration-resistant prostate cancer (CRPC), a fourth potential indication for their PARP inhibitor. The ...
The American Medical Association (AMA) has urged the US Food and Drug Administration (FDA) to work with the medical community to provide transparency around COVID-19 vaccines currently in development.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback